QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
OTCMKTS:MEDXF

Medexus Pharmaceuticals - MEDXF Stock Forecast, Price & News

$1.51
-0.09 (-5.63%)
(As of 12/6/2022 05:34 PM ET)
Add
Compare
Today's Range
$1.48
▼
$1.52
50-Day Range
$0.68
▼
$1.82
52-Week Range
$0.59
▼
$3.50
Volume
13,553 shs
Average Volume
11,602 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.38
MEDXF stock logo

About Medexus Pharmaceuticals (OTCMKTS:MEDXF) Stock

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Receive MEDXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MEDXF Stock News Headlines

November 2, 2022 | finance.yahoo.com
Medexus Schedules Second Quarter 2023 Conference Call
October 2, 2022 | marketwatch.com
Medexus and MidCap Agree to Increase in MidCap's Revolving Loan Commitment Amount
September 19, 2022 | marketwatch.com
Medexus Pharma Says FDA Requests More Information for Treosulfan Drug Application
July 25, 2022 | markets.businessinsider.com
Medexus Pharma Resubmits Treosulfan NDA To FDA
June 22, 2022 | finance.yahoo.com
Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)
June 10, 2022 | benzinga.com
Medexus Pharmaceuticals (OTC:MEDXF), Short Interest Report
June 10, 2022 | benzinga.com
Medexus Pharmaceuticals (OTC:MEDXF), Earnings Estimates, EPS, and Revenue
May 9, 2022 | finance.yahoo.com
Analysts Expect Breakeven For Medexus Pharmaceuticals Inc. (TSE:MDP) Before Long
April 22, 2022 | seekingalpha.com
Medexus, medac refile seeking FDA nod for Treosulfan in cancer patients undergoing stem-cell transplant
April 22, 2022 | finance.yahoo.com
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
April 19, 2022 | finance.yahoo.com
Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference
February 10, 2022 | seekingalpha.com
Medexus Pharmaceuticals reports FQ3 results
February 9, 2022 | finance.yahoo.com
Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021
January 7, 2022 | finance.yahoo.com
Medexus to Present at the H.C. Wainwright BioConnect 2022 Conference
November 10, 2021 | finance.yahoo.com
Medexus to Present at the Q4 Investor Summit on November 17th
November 8, 2021 | finance.yahoo.com
Medexus Pharmaceuticals Announces Appointment of Internal Counsel
November 1, 2021 | finance.yahoo.com
Medexus Pharmaceuticals Announces Type A Meeting with FDA Granted for Treosulfan
October 26, 2021 | finance.yahoo.com
Medexus to Present at the Benzinga Global Small Cap Conference on October 28, 2021
September 16, 2021 | finance.yahoo.com
Medexus Holds Annual and Special Meeting of Shareholders and Announces Election of Board of Directors
August 10, 2021 | finance.yahoo.com
Medexus Pharmaceuticals to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021
August 10, 2021 | finance.yahoo.com
Medexus Schedules First Quarter Fiscal 2022 Conference Call
July 26, 2021 | finance.yahoo.com
The Medexus Pharmaceuticals (TSE:MDP) Share Price Has Gained 98% And Shareholders Are Hoping For More
July 12, 2021 | finance.yahoo.com
Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada
June 14, 2021 | finance.yahoo.com
Medexus to Present at Raymond James Human Health Innovation Conference
June 11, 2021 | benzinga.com
Medexus Schedules Fiscal Year 2021 Conference Call
See More Headlines
Receive MEDXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MEDXF
CUSIP
N/A
CIK
N/A
Web
www.medexus.com
Phone
(514) 344-8765
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.38
High Stock Price Forecast
$2.75
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+57.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Kenneth d'Entremont
    CEO & Director
  • Mr. Marcel Konrad (Age 46)
    Chief Financial Officer
    Comp: $405.77k
  • Mr. Michael David Adelman (Age 51)
    Gen. Mang., U.S. Operations
    Comp: $491.68k
  • Ms. Tina Byers CFA
    Exec. of Investor Relations
  • Mr. Ian C. Wildgoose Brown
    Gen. Counsel & Corp. Sec.
  • Mr. Bill Poncy
    Sr. VP of Commercial Operations - United States
  • Mr. Brian Peters
    VP of Sales & Marketing - United States

Key Competitors

View All Competitors













MEDXF Stock - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MEDXF shares.
View MEDXF analyst ratings or view top-rated stocks.

What is Medexus Pharmaceuticals' stock price forecast for 2023?

1 equities research analysts have issued 12 month price objectives for Medexus Pharmaceuticals' stock. Their MEDXF share price forecasts range from $2.00 to $2.75. On average, they predict the company's share price to reach $2.38 in the next twelve months. This suggests a possible upside of 57.3% from the stock's current price.
View analysts price targets for MEDXF or view top-rated stocks among Wall Street analysts.

How have MEDXF shares performed in 2022?

Medexus Pharmaceuticals' stock was trading at $2.01 at the start of the year. Since then, MEDXF stock has decreased by 24.9% and is now trading at $1.51.
View the best growth stocks for 2022 here.

What is Medexus Pharmaceuticals' stock symbol?

Medexus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "MEDXF."

How do I buy shares of Medexus Pharmaceuticals?

Shares of MEDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medexus Pharmaceuticals' stock price today?

One share of MEDXF stock can currently be purchased for approximately $1.51.

How can I contact Medexus Pharmaceuticals?

Medexus Pharmaceuticals' mailing address is 1, Place du Commerce, Verdun, QC H3E. The official website for the company is www.medexus.com. The company can be reached via phone at (514) 344-8765.

This page (OTCMKTS:MEDXF) was last updated on 12/6/2022 by MarketBeat.com Staff